These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17541852)

  • 21. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.
    Ramasubbu R
    J Psychiatry Neurosci; 1999 Jan; 24(1):45-50. PubMed ID: 9987207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study.
    Pilhatsch M; Wolf R; Winter C; Lewitzka U; Bauer M
    J Affect Disord; 2010 Nov; 126(3):453-7. PubMed ID: 20547424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders.
    Montejo AL; Rico-Villademoros F
    J Sex Marital Ther; 2008; 34(3):227-39. PubMed ID: 18398761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing rapid metabolizers of antidepressants.
    Kraus RP; Diaz P; McEachran A
    Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR.
    DeVane CL
    Psychopharmacol Bull; 2003; 37 Suppl 1():29-41. PubMed ID: 14566199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
    Walker PW; Cole JO; Gardner EA; Hughes AR; Johnston JA; Batey SR; Lineberry CG
    J Clin Psychiatry; 1993 Dec; 54(12):459-65. PubMed ID: 8276736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bupropion-SR-induced increased libido and spontaneous orgasm.
    Labbate LA
    Can J Psychiatry; 1998 Aug; 43(6):644-5. PubMed ID: 9729695
    [No Abstract]   [Full Text] [Related]  

  • 31. Dynamics and persistence of CYP2D6 inhibition by paroxetine.
    Juřica J; Žourková A
    J Clin Pharm Ther; 2013 Aug; 38(4):294-300. PubMed ID: 23437966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics and the pharmacological management of depression.
    Krauter RR; Cook SS
    Nurse Pract; 2011 Oct; 36(10):14-21; quiz 21-2. PubMed ID: 21937968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality.
    Chollet CA; Andreatini R
    J Clin Psychiatry; 2003 Oct; 64(10):1268-9. PubMed ID: 14658981
    [No Abstract]   [Full Text] [Related]  

  • 34. [Combination of serotonergic agents resulted in severe adverse effects].
    Jägestedt M; von Bahr C
    Lakartidningen; 2004 Apr; 101(18):1618-9. PubMed ID: 15185539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.
    Breil F; Verstuyft C; Orostegui L; Buhl C; Alvarez JC; Chouinard G; Becquemont L; Corruble E
    Int J Neuropsychopharmacol; 2008 Aug; 11(5):727-8. PubMed ID: 18384706
    [No Abstract]   [Full Text] [Related]  

  • 36. Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.
    Hole K; Arnestad M; Molden E; Haslemo T
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):281-285. PubMed ID: 33905640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granuloma annulare photoinduced by paroxetine.
    Álvarez-Pérez A; Gómez-Bernal S; Gutiérrez-González E; Rodríguez-Granados MT; Toribio J
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):47-9. PubMed ID: 22212003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.
    Güzey C; Norström A; Spigset O
    Ther Drug Monit; 2002 Jun; 24(3):436-7. PubMed ID: 12021638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.
    Ozdemir V; Tyndale RF; Reed K; Herrmann N; Sellers EM; Kalow W; Naranjo CA
    J Clin Psychopharmacol; 1999 Oct; 19(5):472-5. PubMed ID: 10505591
    [No Abstract]   [Full Text] [Related]  

  • 40. Paroxetine-associated spontaneous sexual stimulation.
    Pae CU; Kim TS; Lee KU; Kim JJ; Lee CU; Lee SJ; Lee C; Paik IH
    Int Clin Psychopharmacol; 2005 Nov; 20(6):339-41. PubMed ID: 16192845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.